Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...

GLP-1 (glucagon-like peptide) medications, such as Ozempic and Wegovy, have seen a surge in popularity over the past few ...

Early adopters of GLP-1 drugs have now lost the weight and are beginning to transition off them. How can F&B support the ...

Fact checked by Nick Blackmer “Microdosing” GLP-1 drugs like Ozempic is gaining attention on social media, but doctors say it ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

The Oklahoma Poison Center is reporting a “surge” of incoming calls about accidental overdosing of popular injectable drugs used for weight loss and diabetes management. Called GLP-1 agonists and used ...

I’m trying to lose the 18 pounds I have gained since the pandemic. It has been hard enough that I’m wondering about Ozempic.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Ignore the noise in GLP-1 stocks. Find the best value instead.

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...